| Cat. No. |
Product Name |
Information |
| PC-21571 |
TY-2136
ROS1/TRK/ALK inhibitor
|
TY-2136 is a next generation ROS1/TRK/ALK inhibitor with IC50 of 1.6 nM and 460.1 nM for ROS1 G2032R and TRKA G595R, respectively, inhibits ROS1/TRK/ALK mutations and overcomes drug resistance due to acquired solvent-front mutations. |
| PC-20952 |
Unecritinib
ALK/ROS1 inhibitor
|
Unecritinib (TQ-B3101) is a novel kinase inhibitor targeting receptor tyrosine kinases including ALK, ROS1 and MET, inhibits AKT phosphorylation and downstream signaling molecules ERK1/2, has IC50 of 142.7 nM for wildtype ROS1. |
| PC-49635 |
NVL-520
ROS1 inhibitor
|
Zidesamtinib (NVL-520, NVL520) is a potent, selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations with IC50 of 0.5-3.5 nM, and 12 nM for ROS1 WT. |
| PC-73061 |
Taletrectinib
ROS1/NTRK inhibitor
|
DS-6051b (Taletrectinib, DS 6051b) is a new-generation selective ROS1/NTRK inhibitor, potently inhibits recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in ATP-competitive manner (IC50=1-10 nM). |
| PC-35262 |
WY-135
ALK/ROS1 inhibitor
|
WY-135 (WY135) is a potent inhibitor of ALK and ROS1 with IC50 of 1.2 and 0.48 nM, respectively. |
| PC-42919 |
Lorlatinib
ALK/ROS1 inhibitor
|
Lorlatinib (PF-06463922) is a potent, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC50 of 0.07/0.025 nM respectively. |
| PC-73163 |
ROS1 fusion inhibitor I
ROS1 fusion inhibitor
|
ROS1 fusion inhibitor I is a carcinogenic fused kinase (Ros1 fusion kinase) inhibitor. |
